Weekly Digest - November 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - November 2024
28 Nov 2024: AstraZeneca’s Enhertu drug added to China’s state insurance list
- AstraZeneca’s Enhertu drug will be included in China’s state-run health insurance scheme starting January 1, making it more accessible to the public
- While the inclusion of Enhertu in the reimbursement list will increase its availability in China, the price will likely decrease by 63% on average, which could reduce potential revenue despite higher sales volume
- Enhertu is designed for breast cancer patients with HER2-positive disease, a condition affecting around 20% of breast cancer patients. Breast cancer is the second most common cancer in women in China, after lung cancer
- China, the world’s second-largest pharmaceutical market, is a key focus for AstraZeneca, contributing 13% of its overall revenue. Enhertu’s inclusion in the insurance scheme reflects AstraZeneca’s deep investment in the region
